Feedback / Questions
lirentelimab subcutaneous (AK002 SC) - Allakos
https://www.globenewswire.com/news-release/2021/11/30/2342880/0/en/Allakos-Announces-Expansion-of-Lirentelimab-Development-into-Atopic-Dermatitis-Chronic-Spontaneous-Urticaria-and-Asthma.html
Nov 30, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next